tirzepatide acute kidney injury Renal effects of GLP-1 receptor agonists and in individuals with type 2 diabetes: seeds of a promising future | Endocrine Interplay of Chronic Kidney Disease

GLP-1/GIP dual agonists combine GLP-1 and GIP into a single molecule

In July 2026, Medicare launches the GLP-1 Bridge pilot, covering GLP-1 receptor agonists for obesity in beneficiaries, with the permanent BALANCE Model following in January 2027

Alcohol Alcohol can provoke atrial fibrillation in susceptible peoplesometimes called holiday heartand also disrupts sleep, which itself raises the risk of palpitations

Many people also notice they feel less tired during long or intense workouts

Advertisement Novo Nordisks Cagrisema, a combination therapy with 2.4mg semaglutide and 2.4mg cagrilintide, an amylin analog, is currently in the phase 3 clinical trial